RU2012103492A - Содержащие фосфор соединения хиназолина и способы применения - Google Patents

Содержащие фосфор соединения хиназолина и способы применения Download PDF

Info

Publication number
RU2012103492A
RU2012103492A RU2012103492/04A RU2012103492A RU2012103492A RU 2012103492 A RU2012103492 A RU 2012103492A RU 2012103492/04 A RU2012103492/04 A RU 2012103492/04A RU 2012103492 A RU2012103492 A RU 2012103492A RU 2012103492 A RU2012103492 A RU 2012103492A
Authority
RU
Russia
Prior art keywords
methyl
alkyl
cycloalkyl
heterocyclyl
heterocyclylalkyl
Prior art date
Application number
RU2012103492/04A
Other languages
English (en)
Russian (ru)
Inventor
Ван ШЕНЬ
Аймин ЧЖАН
Цзюньфа ФАНЬ
Сяолин ЧЖЭН
Original Assignee
Ньюджен Терапьютикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ньюджен Терапьютикс, Инк. filed Critical Ньюджен Терапьютикс, Инк.
Publication of RU2012103492A publication Critical patent/RU2012103492A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6568Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms
    • C07F9/65685Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus atoms as the only ring hetero atoms the ring phosphorus atom being part of a phosphine oxide or thioxide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/74Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/6512Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2012103492/04A 2009-07-02 2010-07-02 Содержащие фосфор соединения хиназолина и способы применения RU2012103492A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22255109P 2009-07-02 2009-07-02
US61/222,551 2009-07-02
PCT/US2010/001897 WO2011002523A1 (en) 2009-07-02 2010-07-02 Phosphorus containing quinazoline compounds and methods of use

Publications (1)

Publication Number Publication Date
RU2012103492A true RU2012103492A (ru) 2013-08-10

Family

ID=43411348

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012103492/04A RU2012103492A (ru) 2009-07-02 2010-07-02 Содержащие фосфор соединения хиназолина и способы применения

Country Status (13)

Country Link
US (1) US8987284B2 (https=)
EP (1) EP2448409A4 (https=)
JP (1) JP5721709B2 (https=)
KR (1) KR20120090025A (https=)
CN (1) CN102711472B (https=)
AU (1) AU2010266725A1 (https=)
BR (1) BRPI1015363A2 (https=)
CA (1) CA2804190A1 (https=)
IL (1) IL217222A0 (https=)
MX (1) MX2012000166A (https=)
RU (1) RU2012103492A (https=)
SG (1) SG177451A1 (https=)
WO (1) WO2011002523A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG177451A1 (en) 2009-07-02 2012-02-28 Newgen Therapeutics Inc Phosphorus containing quinazoline compounds and methods of use
US8916574B2 (en) 2009-09-28 2014-12-23 Qilu Pharmaceutical Co., Ltd. 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
EP2714703B1 (en) 2011-05-31 2021-03-10 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
CN103772411B (zh) * 2013-04-28 2016-08-03 复旦大学 含硫6-呋喃基喹唑啉-4-胺化合物及其制备方法和用途
CN104558040B (zh) * 2015-01-30 2017-04-05 江苏康缘药业股份有限公司 含磷取代的喹唑啉衍生物的晶型及其制备方法和应用
CN104558043B (zh) * 2015-01-30 2017-01-11 江苏康缘药业股份有限公司 含磷取代的喹唑啉衍生物的新晶型及其制备方法和应用
CN104610364B (zh) * 2015-01-30 2017-03-29 江苏康缘药业股份有限公司 含磷取代的喹唑啉衍生物的新晶型及其制备方法和应用
CN104558042B (zh) * 2015-01-30 2017-03-29 江苏康缘药业股份有限公司 含磷取代的喹唑啉衍生物的新晶型及其制备方法和应用
CN104558041B (zh) * 2015-01-30 2017-01-11 江苏康缘药业股份有限公司 含磷取代的喹唑啉衍生物的新晶型及其制备方法和应用
CN105388242A (zh) * 2015-11-11 2016-03-09 江苏康缘药业股份有限公司 二对甲苯磺酸缘生替尼原料药中残留溶剂的检测方法
CN105424831B (zh) * 2015-11-11 2017-11-10 江苏康缘药业股份有限公司 二对甲苯磺酸缘生替尼原料药中有效成分的定量检测方法
CN105237573B (zh) * 2015-11-11 2017-10-24 江苏康缘药业股份有限公司 二对甲苯磺酸缘生替尼的制备方法
CN105606717B (zh) * 2015-11-11 2017-10-24 江苏康缘药业股份有限公司 二对甲苯磺酸缘生替尼原料药中有关物质的检测方法
CN108285421A (zh) * 2018-01-26 2018-07-17 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成拉帕替尼中间体的方法
EP4013749B1 (en) 2019-08-15 2026-03-11 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
CN113995728B (zh) * 2020-07-28 2023-03-14 江苏康缘药业股份有限公司 一种药物组合物及制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
TR200102505T2 (tr) * 1999-02-27 2003-01-21 Boehringer Ingelheim Pharma Kg 4-amino-kinazolin ve kinolin türevleri.
DE19911509A1 (de) 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
ATE377597T1 (de) 1999-07-09 2007-11-15 Glaxo Group Ltd Anilinochinazoline als protein-tyrosin- kinasehemmer
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
DE10217689A1 (de) 2002-04-19 2003-11-13 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
AU2003231765B9 (en) 2002-04-26 2010-01-28 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
WO2004046101A2 (en) 2002-11-20 2004-06-03 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors
DE10307165A1 (de) 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US7223749B2 (en) * 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10349113A1 (de) * 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
JP2007510667A (ja) 2003-11-07 2007-04-26 スミスクライン ビーチャム (コーク) リミテッド 癌の治療法
US20070208023A1 (en) * 2004-04-16 2007-09-06 Smithkline Beecham Corporation Cancer Treatment Method
KR20080098490A (ko) 2006-01-13 2008-11-10 파마시클릭스, 인코포레이티드 티로신 키나제 억제제 및 이의 용도
JP5241513B2 (ja) * 2006-01-26 2013-07-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミノクロトニルアミノ置換キナゾリン誘導体の合成方法
US20080234267A1 (en) 2007-03-20 2008-09-25 Karen Elizabeth Lackey Compounds and Methods of Treatment
SG177451A1 (en) 2009-07-02 2012-02-28 Newgen Therapeutics Inc Phosphorus containing quinazoline compounds and methods of use

Also Published As

Publication number Publication date
MX2012000166A (es) 2012-04-02
SG177451A1 (en) 2012-02-28
CN102711472A (zh) 2012-10-03
AU2010266725A1 (en) 2012-02-23
BRPI1015363A2 (pt) 2015-08-25
CN102711472B (zh) 2015-12-02
US20120196833A1 (en) 2012-08-02
EP2448409A4 (en) 2013-04-10
WO2011002523A1 (en) 2011-01-06
HK1176519A1 (zh) 2013-08-02
IL217222A0 (en) 2012-02-29
EP2448409A1 (en) 2012-05-09
CA2804190A1 (en) 2011-01-06
JP5721709B2 (ja) 2015-05-20
JP2012532100A (ja) 2012-12-13
US8987284B2 (en) 2015-03-24
KR20120090025A (ko) 2012-08-16

Similar Documents

Publication Publication Date Title
RU2012103492A (ru) Содержащие фосфор соединения хиназолина и способы применения
JP2012532100A5 (https=)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
RU2004127925A (ru) N3-алкилированные бензимидазольные производные в качестве ингибиторов мек
JP2013508378A5 (https=)
RU2015121431A (ru) Замещенные производные индол-5-ола и их терапевтическое применение
RU2012112050A (ru) Производные дигидроптеридинона, способ их получения и фармацевтическое применение
RU2014152790A (ru) Пирролопиразоновые ингибиторы танкиразы
JP2011502956A5 (https=)
RU2006109600A (ru) N3-алкилированные бензимидазольные производные в качестве ингибиторов мек
RU2013128448A (ru) Производные триазола в качестве ингибиторов сигнального пути wnt
CY1110676T1 (el) ΠΥΡΑΖΟΛΟ[3,4-b]ΠΥΡΙΔΙΝΙΚΕΣ ΕΝΩΣΕΙΣ, ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΦΩΣΦΟΔΙΕΣΤΕΡΑΣΗΣ
RU2013144571A (ru) Алинзамещенные хиназолины и способы их применения
RU2006112593A (ru) Производные 2, 4-ди(гетеро)ариламинопиримидина в качестве ингибиторов zap-70 и/или syk
RU2020102453A (ru) Фармацевтические композиции
JP2013503139A5 (https=)
RU2006146632A (ru) Производные хиназолинона, полезные в качестве ванилоидных антагонистов
RU2006116628A (ru) Новые производные имидазола и их применение в качестве фармацевтических агентов
RU2012136451A (ru) Композиции и способы улучшения активности протеасомы
RU2011127451A (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-c]ПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ РАКА
RU2016103938A (ru) Модуляторы протеин-тирозинкиназы и способы их применения
JP2012511588A5 (https=)
JP2013536188A5 (https=)
JP2014518544A5 (https=)
RU2008112691A (ru) Азотсодержащее гетероциклическое соединение и его фармацевтическое применение

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20141110